Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday. The move is based on a recommendation from the FDA, the company said. Get the full story at our sister site, Drug […]
Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for the 3 months ended June 30, for bottom-line growth of 25% compared with the same period last year. Get the full story at our sister […]
Pavmed raises $5m in private placement
Pavmed (NSDQ:PAVM) said today it closed a $5 million private placement through the sale of senior notes and Series S warrants. Funding in the private placement came from Scopia Holdings, who elected Dr. David Battleman to New York-based Pavmed’s board of directors as part of the financing. “I look forward to joining the PAVmed team as a […]
Pavmed files for $23m private placement
Pavmed (NSDQ:PAVMU) registered for an upcoming private placement, looking to raise approximately $23.4 million, according to an SEC filing posted this week. The New York-based company will look to offer registered derivative securities from conversion of preferred stock, 10 years potential dividends for preferred stock, exchange of Series A warrants for public warrants and exercise of all warrants, according […]
Hook to step down as Integer CEO | Personnel Moves | March 31 , 2017
Integer Holdings (NYSE:ITGR) said this week that current CEO Thomas Hook has stepped down as the company’s president and CEO, effective immediately, with Joseph Dziedzic taking over as interim prez & CEO. Hook will stay on the Frisco, Texas-based company’s board until the company’s 2017 annual meeting of stockholders, but will not seek re-election. Dziedzic is currently a […]
7 medtech stores we missed this week: March 10, 2017
The FDA and Health Canada cleared a couple medical devices while other companies touted their device studies. Here are 7 medtech stories we missed this week but were still worth mentioning. 1. FDA clears Medela’s neonatal enteral feeding device Medela has received 510(k) clearance from the FDA to market its ENFit Low Dose Tip eternal […]
Pavmed announces upcoming exchange offering
Pavmed (NSDQ:PAVMU) today announced an upcoming registered exchange offering, looking to make its common stock exchangeable for units. Each unit in the offering from the New York-based company will be comprised of a share of common stock and a newly issued warrant, which will be exercisable for a share of common stock at an exercise price […]
PAVmed raises $1.5m in private placement
PAVmed Inc. (NSDQ:PAVMU) said today it raised $1.5 million through a private placement of Series A convertible preferred stock and Series A warrants, with funds slated to support FDA clearance of its 1st product, the PortIO intraosseous infusion system. The New York-based company said it is hopeful for for FDA 510(k) clearance for the PortIO by the […]
PAVmed partners with Boston institutions for antibiotic-eluting ear device
PAVmed Inc. (NSDQ:PAVMU) said today that it inked an exclusive licensing agreement with academic institutions to develop and commercialize antibiotic-eluting resorbable ear tubes based on an aqueous silk technology designed by the institutions. The licensing deal includes agreements with Tufts University, Massachusetts Eye & Ear Infirmary and Massachusetts General Hospital, who developed the aqueous silk technology. As […]
Haemonetics taps ex-Medtronic CIO Burke as new CFO | Personnel Moves August 4, 2016
Haemonetics taps ex-Medtronic CIO Burke as new CFO Haemonetics (NYSE:HAE) said this week it tapped former Medtronic (NYSE:MDT) chief integration officer William Burke as its new chief financial officer, effective August 8. Burker operated as CIO with Medtronic since 2015, serving during the integration of Covidien. Prior to that, he held various finance positions with […]
Pavmed eyes Q4 FDA submission for PortIO vascular access device
Pavmed (NSDQ:PAVMU) said today that it’s planning to submit an application for FDA clearance for its 1st product, the PortIO long-term implantable vascular access device, during the 4th quarter. New York City-based Pavmed said the PortIO device is in the verification and validation testing phase, the final stage of pre-submission testing. The company has 4 other […]
MassDevice Network
@MassDevice
LinkedIn
YouTube